Drugs facing NCE-1 in 2030
1. List of Brexafemme drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8188085 | SCYNEXIS | Antifungal agents |
Aug, 2030
(7 years from now) | |
| US10174074 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| US10927142 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(11 years from now) | |
| US11534433 | SCYNEXIS | Antifungal agents with enhanced activity in acidic pH |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 1, 2026 |
| New Indication (I) | Nov 30, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Jun 1, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 2030-06-01
Market Authorisation Date: 01 June, 2021
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...
Dosage: TABLET;ORAL
BREXAFEMME family patents
8
United States
3
China
3
European Union
2
Hong Kong
1
Croatia
1
Poland
1
RS
1
Spain
1
Canada
1
Portugal
1
Lithuania
1
EA
1
Denmark
1
Japan
1
Australia
1
Slovenia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic